![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Abbott DS, Radford SK, Seed PT et al. 2013. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. American Journal of Obstetrics and Gynecology 208:122.e1–e6.
- Al-Khaduri M, Kadoch IJ, Couturier B et al. 2007. Vasa praevia after IVF: should there be guidelines? report of two cases and literature review. Reproductive Biomedicine Online 14:372–374.
- Bolt LA, Chandiramani M, De Greeff A et al. 2011. The value of combined cervical length measurement and fetal fibronectin testing to predict spontaneous preterm birth in asymptomatic high-risk women. Journal of Maternal-Fetal and Neonatal Medicine 24:928–932.
- International Vasa Praevia Foundation. 2008. International Vasa Praevia Foundation Management Recommendations. Available at: www.vasaprevia.ca/forum/index.php?topic = 89.0 (Accessed 23 March 2013).
- Nishtar A, Wood PL. 2012. Is it time to actively look for vasa praevia? Journal of Obstetrics and Gynaecology 32:413–418.
- RCOG. 2011. Green-top Guideline No. 27. Placenta praevia, placenta praevia accreta and vasa praevia: diagnosis and management. London: Royal College of Obstetricians and Gynaecologists. p 1–26.
- UK NSC. 2008. The UK NSC policy on placenta praevia screening in pregnancy. London: UK National Screening Committee. Available at: www.screening.nhs.uk/placentapraevia (Accessed 23 March 2013).